



(11) **EP 2 512 242 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
09.12.2015 Bulletin 2015/50

(45) Date of publication and mention
of the grant of the patent:
30.09.2015 Bulletin 2015/40

(21) Application number: **10838240.9**

(22) Date of filing: **16.12.2010**

(51) Int Cl.:
C07D 495/04^(2006.01) A61K 31/4365^(2006.01)
A61P 25/28^(2006.01)

(86) International application number:
PCT/US2010/060696

(87) International publication number:
WO 2011/075559 (23.06.2011 Gazette 2011/25)

(54) **NOVEL COMPOUNDS**

NEUARTIGE VERBINDUNGEN

NOUVEAUX COMPOSÉS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **18.12.2009 US 287798 P**

(43) Date of publication of application:
24.10.2012 Bulletin 2012/43

(73) Proprietor: **GlaxoSmithKline Intellectual Property**
Limited
Brentford, Middlesex TW8 9GS (GB)

(72) Inventors:
• **CHEN, Deborah**
Commonwealth 138667 (SG)
• **LEE, Kiew, Ching**
Commonwealth 138667 (SG)

• **TERRELL, Lamont, Roscoe**
PA 19406 (US)

(74) Representative: **Drury, Elizabeth Anne**
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS (GB)

(56) References cited:
EP-A1- 1 505 068 EP-A1- 1 598 354
US-A1- 2007 082 880

• **XU ET AL: 'Catalytic Domain Crystal Structure of**
Protein Kinase C-theta' JBC vol. 279, no. 48, 26
November 2004, pages 50401 - 50409,
XP002376549

EP 2 512 242 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).